Establishment Labs (NASDAQ:ESTA) Stock Price Expected to Rise, BTIG Research Analyst Says

Establishment Labs (NASDAQ:ESTA - Get Free Report) had its price objective raised by equities researchers at BTIG Research from $88.00 to $90.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a "buy" rating on the stock. BTIG Research's target price would suggest a potential upside of 20.60% from the company's current price.

Several other analysts have also recently weighed in on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of Establishment Labs in a research note on Friday, March 27th. Stephens raised their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an "overweight" rating in a report on Wednesday, February 25th. Citigroup reiterated a "neutral" rating on shares of Establishment Labs in a research report on Wednesday. Canaccord Genuity Group boosted their price target on Establishment Labs from $85.00 to $90.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. Finally, Wall Street Zen downgraded Establishment Labs from a "buy" rating to a "hold" rating in a research report on Saturday, March 28th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Establishment Labs has an average rating of "Moderate Buy" and a consensus target price of $87.14.

Establishment Labs Price Performance

Shares of NASDAQ ESTA opened at $74.63 on Thursday. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. The business's 50 day moving average price is $65.42 and its two-hundred day moving average price is $66.41. The company has a market cap of $2.19 billion, a PE ratio of -42.89 and a beta of 1.12. Establishment Labs has a twelve month low of $32.75 and a twelve month high of $83.31.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The company had revenue of $59.88 million during the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. Establishment Labs's revenue for the quarter was up 44.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.70) earnings per share. On average, analysts predict that Establishment Labs will post -0.86 EPS for the current year.

Insider Buying and Selling

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 67,249 shares of the business's stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $70.78, for a total transaction of $4,759,884.22. Following the completion of the transaction, the director owned 1,040,255 shares of the company's stock, valued at approximately $73,629,248.90. The trade was a 6.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 225,000 shares of company stock worth $14,935,438 over the last three months. 9.99% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Establishment Labs

A number of institutional investors have recently added to or reduced their stakes in the stock. Sigma Planning Corp boosted its position in Establishment Labs by 325.5% in the first quarter. Sigma Planning Corp now owns 20,424 shares of the company's stock valued at $1,160,000 after buying an additional 15,624 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new position in shares of Establishment Labs during the first quarter worth $209,000. Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Establishment Labs by 20.4% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 5,450 shares of the company's stock worth $309,000 after buying an additional 925 shares in the last quarter. Cannon Global Investment Management LLC bought a new position in shares of Establishment Labs in the 1st quarter valued at $738,000. Finally, Brian Low Financial Group LLC lifted its stake in shares of Establishment Labs by 10.2% in the 1st quarter. Brian Low Financial Group LLC now owns 4,598 shares of the company's stock valued at $261,000 after acquiring an additional 424 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.